Non-steroidal anti-inflammatory drugs in the treatment of genitourinary malignancies: Focus on clinical data

Expert Opinion on Investigational Drugs

Volumn 16, Issue 11, 2007, Pages 1841-1849

  Giannitsas, Konstantinos ^a   Konstantinopoulos, Agelis ^a   Perimenis, Petros ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Bladder cancer; COX 2 inhibitors; NSAIDs; Prostate cancer; Renal cancer

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; BCG VACCINE; CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTRAMUSTINE PHOSPHATE; ETORICOXIB; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIOGLITAZONE; PIROXICAM; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROTEIN P73; ROFECOXIB; SULINDAC; SULINDAC SULFONE; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BONE METASTASIS; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CYSTECTOMY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY CANCER; KIDNEY DISEASE; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NONHUMAN; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; UROGENITAL TRACT CANCER; ANIMAL; BLADDER TUMOR; KIDNEY TUMOR; MALE; METABOLISM; PROSTATE TUMOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CYCLOOXYGENASE 2; HUMANS; KIDNEY NEOPLASMS; MALE; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 36049016233     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.11.1841     Document Type: Review

References (72)

1. SCHOTTENFELD D, BEEBE-DIMMER J: Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J. Clin. (2006) 56(2):69-83.
2. SIMMONS DL, BOTTING RM, HLA T: Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. (2004) 56(3):387-437.
3. BRESALIER RS, SANDLER RS, QUAN H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. (2005) 352(11):1092-1102.
4. SOLOMON SD, MCMURRAY JJ, PFEFFER MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl. J. Med. (2005) 352(11):1071-1080.
5. MERIC JB, ROTTEY S, OLAUSSEN K et al.: Cyclooxygenase-2 as a target for anticancer drug development. Crit. Rev. Oncol. Hematol. (2006) 59(1):51-64.
6. MAHMUD S, FRANCO E, APRIKIAN A: Prostate cancer and use of nonsteroidal anti-inflammarory drugs: systematic review and meta-analysis. Br. J. Cancer (2004) 90(1)93-99.
7. PLATZ EA, ROHRMANN S, PEARSON JD et al.: Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore longitudinal study of aging. Cancer Epidemiol. Biomark. Prev. (2005) 14(2):390-396.
8. JACOBS EJ, RODRIGUEZ C, MONDUL AM et al.: A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J. Natl. Cancer Inst. (2005) 97(13):975-980.
9. GUPTA S, SRIVASTAVA M, AHMAD N, BOSTWICK DG, MUKHTAR H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate (2000) 42(1):73-78.
10. YOSHIMURA R, SANO H, MASUDA C et al.: Expression of cyclooxygenase-2 in prostate carcinoma. Cancer (2000) 89(3):589-596.
11. MADAAN S, ABEL PD, CHAUDHARY KS et al.: Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int. (2000) 86(6):736-741.
12. WANG W, BERGH A, DAMBER JE: Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularizaiion in human prostate cancer. Clin. Cancer Res. (2005) 11(9):3250-3256.
13. UOTILA P, VALVE E, MARTIKAINEN P, NEVALAINEN M, NURMI M, HARKONEN P: Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol. Res. (2001) 29(1):23-28.
14. ZHA S, GAGE WR, SAUVAGEOT J et al.: Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. (2001) 61(24):8617-8623.
15. SHAPPELL SB, MANNING S, BOEGLIN WE et al.: Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia (2001) 3(4):287-303.
16. KIRSCHENBAUM A, KLAUSNER AP, LEE R et al.: Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology (2000) 56(4):671-676.
17. EDWARDS J, MUKHERJEE R, MUNRO AF, WELLS AC, ALMUSHATAT A, BARTLETT JM: HER2 and COX2 expression in human prostate cancer. Eur. J. Cancer (2004) 40(1):50-55.
18. PRUTHI RS, DERKSEN JE, MOORE D: A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int. (2004) 93(3):275-278.
19. PRUTHI RS, DERKSEN JE, MOORE D et al.: Phase II trial of celecoxib in prostare-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin. Cancer Res. (2006) 12(7):2172-2177.
20. SMITH MR, MANOLA J, KAUFMAN DS et al.: Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J. Clin. Oncol. (2006) 24(18):2723-2728.
21. SOORIAKUMARAN P, MACANAS-PIRARD P, FOX S et al.: A blinded, randomized controlled trial of neoadjuvant celecoxib in patients with early prostate cancer. J. Clin. Oncol. (2006) 24(18S):4563.
22. KASIMIS B, CHANG V, COGSWELL j et al.: Combination therapy with docetaxel (D) and celecoxib (C) in patients (pts) with hormone resistant prostate cancer (HRPC). J. Clin. Oncol. (2006) 24(18S):14519.
23. CHANG VT, SAMBAMOORTHI N, YAN H et al.: Quality of life (QOL) in patients (pts) with hormone resistant prostate cancer (HRPC) treated with docetaxel (D) and celecoxib (C). J. Clin. Oncol. (2006) 24(18S):18598.
24. PFISTER C, ALBOUY B, TOURANI J: Preliminary results of biweekly docetaxel in combination with celecoxib in hormone refractory prostate cancer. Proc. ASCO 2007 Prostate Cancer Symp. (Abstract 237).
25. KATTAN J, BACHOUR M, FARHAT F et al.: Phase II trial of weekly docetaxel, zoledronate and celecoxib for androgen-independent prostate cancer patients. Proc. ASCO 2006 Prostate Cancer Symp. (Abstract 362).
26. PHILIPS G, KINAMAN K, PLANTE M et al.: Phase II study of thalidomide and celecoxib in androgen independent prostate cancer (AIPC). J. Clin. Oncol. (2005) 23(16S):4732.
27. ZHONG F, KASIMIS B, CHANG V et al.: A Phase II trial of epirubicin (E), estramustine phosphate (EP), and celecoxib (C) as second line treatment of patients (pts) with hormone resistant prostate cancer (HRPC). J. Clin. Oncol. (2006) 24(18S):14567.
28. MELLADO B, FONT A, CARLES J et al.: A Phase II study of weekly docetaxel (T), estramustine (E), and celecoxib (C) in patients with hormone refractory prostate cancer (HRPC). J. Clin. Oncol. (2005) 23(16S):4725.
29. SWABB EA, QUIGGLE DD, GUTIERREZ I et al.: Multi-dose Phase I trial of MCP-7869 in prostate cancer patients with increasing prostate specific antigen (PSA). Proc. Am. Assoc. Cancer Res. (2002) 43:749 (Abstract 3714).
30. GOLUBOFF ET, PRAGER D, RUKSTALIS D et al.: Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J. Urol. (2001) 166(3):882-886.
31. PRAGER D, GOLUBOFF E, RUCKSTALIS D et al.: Long-term use of exisulind in men with prostate cancer following radical prostatectomy. Proc. Am. Soc. Clin. Oncol. (2002) 21(184a):(Abstract 733).
32. MURASAKI G, ZENSER TV, DAVIS BB, COHEN SM: Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis. Carcinogenesis (1984) 5(1):53-55.
33. KLÄN R, KNISPEL HH, MEIER T: Acetylsalicylic acid inhibition of N-butyl-(4-hydroxybutyl) nitrosamine-induced bladder carcinogenesis in rats. J. Cancer Res. Clin. Oncol. (1993) 119(8):482-485.
34. GRUBBS CJ, JULIANA MM, ETO I et al.: Chemoprevention by indomethacin of N-butyl-N(4-hydroxbutyl)- nitrosamine-induced urinary bladder tumors. Anticancer Res. (1993) 13(1):33-36.
35. SHIBATA MA, HASEGAWA R, SHIRAI T, TAKESADA Y, FUKUSHIMA S: Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model. Int. J. Cancer (1993) 55(6):1011-1017.
36. RAO KV, DETRISAC CJ, STEELE VE, HAWK ET, KELLOFF GJ, MCCORMICK DL: Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis (1996) 17(7):1435-1438.
37. MOON RC, KELLOFF GJ, DETRISAC CJ, STEELE VE, THOMAS CF, SIGMAN CC: Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis (1993) 14(7):1487-1489.
38. OKAJIMA E, DENDA A, OZONO S et al.: Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N(4-hydroxybutyl) nitrosamine. Cancer Res. (1998) 58(14):3028-3031.
39. MARGULIS V, SHARIAT SF, ASHFAQ R et al.: Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J. Urol. (2007) 177(3):1163-1168.
40. MOHAMMED SI, KNAPP DW, BOSTWICK DG et al.: Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. (1999) 59(22):5647-5650.
41. KOMHOFF M, GUAN Y, SHAPPELL HW et al.: Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am. J. Pathol. (2000) 157(1):29-35.
42. SHIRAHAMAT: Cyclooxygenase-2 expression is upregulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin. Cancer Res. (2000) 6(6):2424-2430.
43. YOSHIMURA R, SANO H, MITSUHASHI M, KOHNO M, CHARGUI J, WADA S: Expression of cyclooxygenase-2 in patients with bladder carcinoma. J. Urol. (2001) 165(5):1468-1472.
44. RISTIMAKI A, NIEMINEN O, SAUKKONEN K, HOTAKAINEN K, NORDLING S, HAGLUND C: Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am. J. Pathol. (2001) 158(3):849-853.
45. MOHAMMED SI, BENNETT PF, CRAIG BA et al.: Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. (2002) 62(2):356-358.
46. GEE J, LEE IL, JENDIROBA D, FISCHER SM, GROSSMAN HB, SABICHI AL: Selective cyclooxygcnase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol. Rep. (2006) 15(2):471-477.
47. FABBRI F, BRIGLIADORI G, ULIVI P et al.: Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells. Apoptosis (2005) 10(5):1095-1103.
48. HATTORI K, IIDA K, JORAKU A, TSUKAMOTO S, AKAZA H, OYASU R: Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int. (2006) 97(3):640-643.
49. MIZUTANI Y, NAKANISHI H, LI YN, SATO N, KAWAUCHI A, MIKI T: Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. J. Urol. (2004) 172(4 Part 1):1474-1479.
50. CASTELAO JE, YUAN JM, GAGO-DOMINGUEZ M, YU MC, ROSS RK: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br. J. Cancer (2000) 82(7):1364-1369.
51. SHEEHY OE, ZHAO SZ, RAYMOUNDO AL, MILLER B, APRIKLAN AG, LELORIER J: Celecoxib associated with reduced risk of superficial bladder cancer (SBC) recurrence. Proc. Am. Soc. Clin. Oncol. (2003) 22:(Abstract 1539).
52. CHEN Q, SHINORARA N, ABE T, WATANABE T, NONOMURA K, KOYANAGI T: Significance of COX-2 expression in human renal cell carcinoma cell lines. Int. J. Cancer (2004) 108(6):825-832.
53. MATSUYAMA M, YOSHIMURA R, MITSUHASHI M et al.: 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol. Rep. (2005) 14(1):73-79.
54. MIYATA Y, KOGA S, KANDA S, NISHIKIDO M, HAYASHI T, KANETAKE H: Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with rumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin. Cancer Res. (2003) 9(5):1741-1749.
55. HASHIMOTO Y, KONDO Y, KIMURA G et al.: Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology (2004) 44(4):353-359.
56. TUNA B, YORUKOGLU K, GUREL D, MUNGAN U, KIRKALI Z: Significance of COX-2 expression in human renal cell carcinoma. Urology (2004) 64(6):1116-1120.
57. YOSHIMURA R, MATSUYAMA M, KAWAHITO Y et al.: Study of cyclooxygenase-2 in renal cell carcinoma. Int. J. Mol. Med. (2004) 13(2):229-233.
58. REICHLE A, GRASSINGER J, BROSS K et al.: Effect of anti-inflammatory therapy in patients with metastatic renal cell carcinoma on clinical response. J. Clin. Oncol. (2006) 24(18S):14500.
59. RINI BI, WEINBERG V, DUNLAP S et al.: Maxi trial COX-2 immunostaining and clinical response to celecoxib and interferon-α therapy in metastatic renal cell carcinoma. Cancer (2006) 106(3):566-575.
60. KRZYZANOWSKA M, TANNOCK I, LOCKWOOD G, KNOX J, MOORE M, BJARNASON G: A Phase II trial of Continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother. Pharmacol. (2007) 60(1):135-141.
61. DE MARZO AM, PLATZ EA, SUTCLIFFE S et al.: Inflammation in prostate carcinogenesis. Nat. Rev. Cancer (2007) 7(4):256-269.
62. PLATZ EA, DE NLARZO AM: Epidemiology of inflammation and prostate cancer. J. Urol. (2004) 171(2 Part 2):S36-S40.
63. MICHAUD DS: Chronic inflammation and bladder cancer. Urol. Oncol. (2007) 25(3):260-268.
64. PATFL MI, SUBBARAMAIAH K, DU B et al.: Cclecoxib inhibits prostate cancer growth: evidence of a cyclooxygenasc-2-independent mechanism. Clin. Cancer Res. (2005) 11(5):1999-2007.
65. FLAYASHI T, NISHIYAMA K, SHIRAHAMA T: Inhibition of 5-lipoxygenase pathway suppresses the growth of bladder cancer cells. Int. J. Urol. (2006) 13:1086-1091.
66. GARCIA-RODRIGUEZ LA, BARREALES-TOLOSA L: Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology (2007) 132(2):498-506.
67. MCGETTIGAN P, HENRY D: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational Studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA (2006) 296(13):1633-1644.
68. ANDREWS P, ZHAO X, ALLEN JV, LI F, CHANG MA: Comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother. Pharmacol. (2007) (In Press).
69. DOVEDI SJ, KIRBY JA, ATKINS H, DAVIES BR, KELLY JD: Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of Bacillus calmette-guerin immunotherapy for bladder cancer. J. Urol. (2005) 174(1):332-337.
70. GARCIA JA, RINI BI: Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin. (2007) 57(2):112-125.
71. GOLIJANIN D, TAN JY, KAZIOR A et al.: Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin. Cancer Res. (2004) 10(3):1024-1031.
72. HASE T, YOSHIMURA R, MATSUYAMA M et al.: Cyclooxygenase-1 and -2 in human resticular tumours. Eur. J. Cancer (2003) 39(14):2043-2049.